Celltrion/Pfizer Agree To Wait For Mid-Sept US Inflectra Launch

Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar product Inflectra in the US pending an ongoing legal dispute, have agreed to wait a little bit longer – now until after Sept. 15 under a stipulation with Janssen Biotech Inc., whose monoclonal antibody Remicade was the reference drug.